Ben Adams for Pharmatimes, 6th September 2012, quotes Julia Manning on Jeremy Hunt and value-based pricing.
Click here to read the article in full.
“VBP discussions to be delayed?
The first clash could be VBP – as he [Jeremy Hunt] will now walk straight into negotiations with the ABPI over the future of drug pricing in the UK. But Julia Manning, chief executive of the industry think-tank 2020Health, says it would be sensible for Hunt to postpone the discussions.
She told PharmaTimes that as the government has to renegotiate the PPRS regardless of what happens: “It would seem sensible for [Hunt] to focus on this and postpone negotiations on changing the pricing system for new drugs”.
She added: “This gives everyone more time to think about what data and structures would be required for a new system to be truly effective with no detriment to the pharmaceutical industry’s investment in research, clinical trials and above all patients in the UK.” Whatever happens, a new system will have to be in place by 2014 as this is when the current five-year PPRS scheme ends.”